nach oben

Neurotherapeutics

Erschienen in:

01.04.2012 | Editorial

Animal Models of Neurological Disorders

verfasst von: Marie-Francoise Chesselet, S. Thomas Carmichael

Erschienen in: Neurotherapeutics | Ausgabe 2/2012

Einloggen, um Zugang zu erhalten

Excerpt

Animal modeling of human disease is a cornerstone to basic scientific studies of disease mechanisms and pre-clinical studies of potential therapies. Rapid progress in animal modeling has led to advancements in the understanding of fundamental disease mechanisms of many central nervous system (CNS) disorders, including initial cell death and later repair in stroke [1, 2], motor and nonmotor pathologies in Parkinson’s Disease [3, 4], and axonal regeneration in peripheral and optic nerve injury [5, 6], among many others. Ideally, animal modeling produces basic insights, new views of the human disease, and preclinical trials of novel therapies. Much progress has been accomplished in that direction since the earlier coverage of this topic in the issue of Neurotherapeutics in July 2005. Yet controversy and challenges in animal modeling of human CNS diseases continue to occur. …

Nur mit Berechtigung zugänglich

Carmichael ST. Animal models of stroke: size, mechanism and purpose. NeuroRx 2005;2:396–409.CrossRefPubMed

Murphy TH, Corbett D. Plasticity during stroke recovery: from synapse to behaviour. Nat Rev Neurosci 2009;10:861–872.CrossRefPubMed

Dunnett SB, Lelos M. Behavioral analysis of motor and non-motor symptoms in rodent models of Parkinson's disease. Prog Brain Res 2010;184:35–51.CrossRefPubMed

Chesselet M-F, Richter F, Zhu C, Magen I, Watson MB, Subramaniam SR. A Progressive Mouse Model of Parkinson’s Disease: The Thy1-aSyn Mice. Neurotherapeutics 2012. doi:10.1007/s13311-012-0104-2 (in this issue).CrossRefPubMed

Limb GA, Martin KR. Sixth ARVO/Pfizer Ophthalmics Research Institute Conference Working Group. Current prospects in optic nerve protection and regeneration: sixth ARVO/Pfizer Ophthalmics Research Institute conference. Invest Ophthalmol Vis Sci 2011;;52:5941–5954.CrossRefPubMed

Wood MD, Kemp SW, Weber C, Borschel GH, Gordon T. Outcome measures of peripheral nerve regeneration. Ann Anat 2011;193:321–333

O’Collins VE, Macleod MR, Donnan GA, Horky LL, van der Worp BH, Howells DW. 1,026 experimental treatments in acute stroke. Ann Neurol 2006;59:467–477.CrossRefPubMed

Sena ES, van der Worp HB, Bath PM, Howells DW, Macleod MR. Publication bias in reports of animal stroke studies leads to major overstatement of efficacy. PLoS Biol 2010;8:e1000344.CrossRefPubMed

Scott S, Kranz JE, Cole J, et al. Design, power, and interpretation of studies in the standard murine model of ALS. Amyotroph Lateral Scler 2008;9:4–15.CrossRefPubMed

10.

Benatar M. Lost in translation: treatment trials in the SOD1 mouse and in human ALS. Neurobiol Dis 2007;26:1–13.CrossRefPubMed

11.

Gordon PH, Moore DH, Miller RG, et al. Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial. Lancet Neurol 2007;6:1045–1053.CrossRefPubMed

12.

Macleod MR, van der Worp HB, Sena ES, Howells DW, Dirnagl U, Donnan GA. Evidence for the efficacy of NXY-059 in experimental focal cerebral ischaemia is confounded by study quality. Stroke 2008;39:2824–2829.CrossRefPubMed

13.

Lohle M, Reichmann H. Clinical neuroprotection in Parkinson's disease — still waiting for the breakthrough. J Neurol Sci 2010;289:104–114.CrossRefPubMed

14.

Auvin S, Pineda E, Shin D, Gressens P, Mazarati A. Novel Animal Models of Pediatric Epilepsy. Neurotherapeutics 2012. doi:10.1007/s13311-012-0119-8 (in this issue).

15.

Höke A. Animal Models of Peripheral Neuropathies. Neurotherapeutics 2012. doi:10.1007/s13311-012-0116-y (in this issue).

16.

The Huntington’s Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington’s disease chromosomes. Cell 1993;72:971–983.CrossRef

17.

Ehrlich ME. Huntington’s Disease and the Striatal Medium Spiny Neuron: Cell-Autonomous and Non-Cell-Autonomous Mechanisms of Disease. Neurotherapeutics 2012. doi:10.1007/s13311-012-0112-2 (in this issue).

18.

Dürr A, Stevanin G, Cancel G, Duyckaerts C, Abbas N, Didierjean O, Chneiweiss H, Benomar A, Lyon-Caen O, Julien J, Serdaru M, Penet C, Agid Y, Brice A. Spinocerebellar ataxia 3 and Machado-Joseph disease: clinical, molecular, and neuropathological features. Ann Neurol 1996;39:490–499.

19.

Colomer Gould VF. Mouse Models of Spinocerebellar Ataxia Type 3 (Machado-Joseph Disease). Neurotherapeutics 2012. doi:10.1007/s13311-012-0117-x (in this issue).

20.

Fremont R, Khodakhah K. Alternative Approaches to Modeling Hereditary Dystonias. Neurotherapeutics 2012. doi:10.1007/s13311-012-0113-1 (in this issue).

21.

Bubier JA, Chesler EJ. Accelerating Discovery for Complex Neurological and Behavioral Disorders through Systems Genetics and Integrative Genomics in the Laboratory Mouse. Neurotherapeutics 2012. doi:10.1007/s13311-012-0111-3 (in this issue).

22.

Courtine G, Bunge MB, Fawcett JW, et al. Can experiments in nonhuman primates expedite the translation of treatments for spinal cord injury in humans? Nat Med 2007;13:561–566.CrossRefPubMed

23.

Zhang K, Sejnowski TJ. A universal scaling law between gray matter and white matter of cerebral cortex. Proc Natl Acad Sci U S A 2000;97:5621–5626.CrossRefPubMed

24.

Back SA, Riddle A, Dean J, Hohimer AR. The Instrumented Fetal Sheep as a Model of Cerebral White Matter Injury in the Premature Infant. Neurotherapeutics 2012. doi:10.1007/s13311-012-0108-y (in this issue).

25.

Cook DJ, Tymianski M. Nonhuman Primate Models of Stroke for Translational Neuroprotection Research. Neurotherapeutics 2012. doi:10.1007/s13311-012-0115-z (in this issue).

26.

Rosenzweig ES, Courtine G, Jindrich DL, et al. Extensive spontaneous plasticity of corticospinal projections after primate spinal cord injury. Nat Neurosci 2010;13:1505–1510.CrossRefPubMed

27.

Rosenzweig ES, Brock JH, Culbertson MD, et al. Extensive spinal decussation and bilateral termination of cervical corticospinal projections in rhesus monkeys. J Comp Neurol 2009;513:151–63.CrossRefPubMed

28.

Nout YS, Rosenzweig ES, Brock JH, Strand SC, Moseanko R, Hawbecker S, Zdunowski S, Nielson JL, Roy RR, Courtine G, Ferguson AR, Edgerton VR, Beattie MS, Bresnahan JC, Tuszynski MH. Animal Models of Neurologic Disorders: A NonhumanPrimate Model of Spinal Cord Injury. Neurotherapeutics 2012. doi:10.1007/s13311-012-0114-0 (in this issue).

Titel: Animal Models of Neurological Disorders
verfasst von: Marie-Francoise Chesselet
S. Thomas Carmichael
Publikationsdatum: 01.04.2012
Verlag: Springer-Verlag
Erschienen in: Neurotherapeutics / Ausgabe 2/2012
Print ISSN: 1933-7213
Elektronische ISSN: 1878-7479
DOI: https://doi.org/10.1007/s13311-012-0118-9

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Viel Bewegung in der Parkinsonforschung

25.04.2024 Parkinson-Krankheit Nachrichten

Neue arznei- und zellbasierte Ansätze, Frühdiagnose mit Bewegungssensoren, Rückenmarkstimulation gegen Gehblockaden – in der Parkinsonforschung tut sich einiges. Auf dem Deutschen Parkinsonkongress ging es auch viel um technische Innovationen.

Demenzkranke durch Antipsychotika vielfach gefährdet

23.04.2024 Demenz Nachrichten

Wenn Demenzkranke aufgrund von Symptomen wie Agitation oder Aggressivität mit Antipsychotika behandelt werden, sind damit offenbar noch mehr Risiken verbunden als bislang angenommen.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2012

A Novel “Molecular Tweezer” Inhibitor of α-Synuclein Neurotoxicity in Vitro and in Vivo

Models That Matter: White Matter Stroke Models

Nonhuman Primate Models of Stroke for Translational Neuroprotection Research

Recovery of MERRF Fibroblasts and Cybrids Pathophysiology by Coenzyme Q10

Interleukin-1beta Causes Fluoxetine Resistance in an Animal Model of Epilepsy-Associated Depression

Genetic Manipulation of Cell Death and Neuroplasticity Pathways in Traumatic Brain Injury